Table 2.

Comparison between the patients treated with TCZ and those who treated with other advanced anti-inflammatory drugs.

	Anti-inflammatory treatment		p-value
	Tocilizumab	Other
Age (years), median (IQR)	75.3 (65.3–85.2)	50.2 (33.3–65.6)	<0.001
Male	35.7%	46.3%	0.434
Diagnosis of infectious disease on admission	50.0%	23.4%	0.050
Concurrent steroids use	35.7%	34.6%	>0.999
Comorbidities
IHD
CVD	0.0%	4.4%	>0.999
CHF	14.3%	3.1%	0.083
DM	7.1%	12.5%	>0.999
COPD	42.9%	9.5%	0.002
PVD
Renal disease	14.3%	5.8%	0.210
Liver disease	0.0%	4.1%	>0.999
Tumor	7.1%	5.8%	0.576
Lymphoma	7.1%	1.0%	0.170
Peptic ulcer	0.0%	1.7%	>0.999
AIDS	0.0%	0.3%	>0.999
Charlson Score, median (IQR)	5 (4.8–6.3)	1 (0–3)	<0.001
Blood tests
CRP (mg/dL), median (IQR)	0.5 (0.05–21.21)	25.06 (7.25–94.86)	<0.001
WBC (K/μL), median (IQR),	9.3 (6.4–11.5)	8.5 (6.3–11.1)	0.720
Neutrophils (K/μL), median (IQR)	6.6 (4.0–8.9)	5.6 (3.8–8.3)	0.711
Lymphocytes (K/μL), median (IQR)	1.7 (0.9–2.1)	1.7 (1.2–2.3)	0.631
PLT (K/μL), median (IQR)	149 (124–210)	238 (184–308)	<0.001
Albumin (g/L), mean (SD)	38 (3.9)	36.6 (5.8)	0.384
Creatinine (mg/dL), median (IQR)	0.78 (0.6–1.17)	0.80 (0.65–0.99)	0.988
Vital signs
Heart rate, mean (SD), bpm	80.7 (13.4)	81.2 (16.1)	0.896
SBP, mean (SD), mmHg	136.9 (18.7)	126.9 (21.6)	0.085
DBP, mean (SD), mmHg	75.1 (10.5)	73.7 (14.0)	0.748
Body temperature, mean (SD),C०	36.6 (0.4)	36.8 (0.5)	0.176

IHD - Ischemic heart disease; CVD - Cardiovascular diseases; CHF - Congestive heart failure; DM - Diabetes mellitus; COPD - Chronic obstructive pulmonary disease; PVD - Peripheral Vascular Disease; CRP - C-reactive protein; WBC - White blood cells; PLT - Platelets; SBP - Systolic blood pressure; DBP - Diastolic blood pressure.